Difference between revisions of "Team:TU Dresden/Project/Description"

 
(184 intermediate revisions by 3 users not shown)
Line 9: Line 9:
 
#TueContent table img {
 
#TueContent table img {
 
   width: 250px;
 
   width: 250px;
   display: block;  
+
   display: block;
   margin-left: auto;  
+
   margin-left: auto;
 
   margin-right: auto;
 
   margin-right: auto;
 
   padding-bottom: 20px;
 
   padding-bottom: 20px;
Line 26: Line 26:
  
 
#TueContent img {
 
#TueContent img {
    display: block;
+
  display: block;
    margin-left: auto;
+
  margin-left: auto;
    margin-right: auto;
+
  margin-right: auto;
    width: 100%;
+
 
}
 
}
  
 
p.big {
 
p.big {
    line-height: 1000%;
+
  line-height: 1000%;
 
}
 
}
 +
 +
.circular {
 +
width: 250px;
 +
height: 250px;
 +
border-radius: 15px;
 +
-webkit-border-radius: 150px;
 +
-moz-border-radius: 150px;
 +
}
 +
 +
.notbold{
 +
    font-weight:normal
 +
}​
 
</style>
 
</style>
 
</head>
 
</head>
 +
 +
 
<body>
 
<body>
</style>
 
  
 +
  <div id="TueContent">
 +
<p></p>
 +
<h1>Description</h1>
 +
<p></p>
 +
<h2>Introduction</h2>
 +
<p style="line-height:1.8">Our project is called <b>SPACE-P</b> (Structural Phage Assisted Continuous Evolution of Proteins) and is part of the Synthetic Biology field. It focuses on accelerating the process of developing protein binding partners, which is required in pharmaceutical research as well as biotechnology and many other fields of science. Thus far phage display is the most commonly used method for the discovery of protein binding partners. In this method a large library of potential binding partners is created where the strongest candidates are selected for further affinity testing. This process is very time consuming, cost intensive, requires human intervention steps, and is limited to the size of the given library. Our platform will make it possible to start with a single molecule, transform it by mutation and selection pressure to improve the binding affinity towards a target protein. This method is not only easy to implement, utilizing simple organisms and devices, but also significantly faster and cheaper than currently used tools. </p>
  
</head>
+
  <h2>Subprojects</h2>
 +
  <p style="line-height:1.8">To establish our idea we divided the whole work into subprojects which were realized simultaniously. These subprojects should be combined later. The error finding and erasing is much easier with this approach and it is faster compared to a step by step approach where you try to start with the next step only when you succeeded the previous ones. The subprojects we worked on are the following:</p>
 +
 
 +
  <p style="line-height:1.8"><ul>
 +
    <li style="margin-bottom: 10px;line-height:1.8;"><a style="text-decoration:none;" href="https://2015.igem.org/Team:TU_Dresden/Project/Description#folding"><font color="#045FB4">Folding study of target protein</font></a></li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;"><a style="text-decoration:none;" href="https://2015.igem.org/Team:TU_Dresden/Project/Description#structure"><font color="#045FB4">Structure analysis of our targets and their interactions</font></a></li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;"><a style="text-decoration:none;" href="https://2015.igem.org/Team:TU_Dresden/Project/Description#resistance"><font color="#045FB4">Investigation of P3 threshold for <i>E. coli</i> resistance</font></a></li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;"><a style="text-decoration:none;" href="https://2015.igem.org/Team:TU_Dresden/Project/Description#bacth"><font color="#045FB4">Conversion of BACTH into an iGEM standard and analysis of function</font></a></li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;"><a style="text-decoration:none;" href="https://2015.igem.org/Team:TU_Dresden/Project/Description#setup"><font color="#045FB4">Set up of flow system</font></a></li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;"><a style="text-decoration:none;" href="https://2015.igem.org/Team:TU_Dresden/Project/Description#biobrick"><font color="#045FB4">Biobrick assembly</font></a></li>
 +
  </ul>
 +
  <p></p>
 +
 
 +
  <h3 id="folding">Folding study of target protein</h3>
 +
  <a href="https://2015.igem.org/Team:TU_Dresden/Project/Description#folding"></a>
 +
 
 +
  <p style="line-height:1.8">As a proof of principle we wanted to fit an affibody to the epitope of a target protein. The target we chose for our studies is a human membrane protein called human epidermal growth factor receptor 2 (HER2). To use a human protein and membrane protein is challenging since the codon usage, post-translational modifications, disulfide bridges and membrane parts have to be taken into account. To deal with this challenges we decided for a small extracellular domain that carries no  post-translational modifications and disulfide bridges. This part of HER2 is involved in ligand binding and therefore is an interesting drug target. Afterwards we harmonized the codon usage to <i>E. coli</i>. Finally we compared the protein structure expressed from <i>E. coli</i> to the expected one from literature. To do so we cloned the fragment into an expression vector with a tag, purified it with a column and analyse it with circular dichroism spectroscopy.</p>
 +
 
 +
<p>
 +
  <h3 id="structure">Structure analysis of our targets and their interactions</h3>
 +
  <a href="https://2015.igem.org/Team:TU_Dresden/Project/Description#structure"></a>
 +
 
 +
  <p style="line-height:1.8">Having the crystallized structure of the extracellular part of HER2 and the affibody ZHER2 binding to it (PDB-ID: 3MZW), we are able to perform further investigations on our targets and their interactions. Those analysis should give us a presentiment of possibilities for the directed evolution and therefore provide a benchmark for the choice of further possible targets.
 +
  The following analysis are performed:
 +
  <ul>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">Structure check of HER2</li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">Calculation of interfacial residues of HER2 and its bound affibody</li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">Calculation of electrostatic interactions in the interface</li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">Conservation study of HER2</li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">Visualization of the B-factor for the affibody ZHER2</li>
 +
 
 +
  </ul>
 +
 
 +
</p>
 +
 
 +
 
 +
  <h3 id="resistance">Investigation of P3 threshold for <i>E. coli</i> resistance</h3>
 +
  <a href="https://2015.igem.org/Team:TU_Dresden/Project/Description#resistance"></a>
 +
 
 +
  <p style="line-height:1.8;">The protein III (P3) from M13 plays a key role in our concept. The deficiency of it in the M13 phage we used can be compensated by the modified <i>E. coli</i>. However it is known that the expression of P3 in <i>E. coli</i> before the infection with M13 leads to the resistance of the bacterium to the phage. This was our motivation to find the threshold of resistance. To find it we measured the amount of infected bacteria cells in the lagoon depending on the expression rate of P3. The P3 expression rate should be detected by the co-expression of a fluorescent protein while the amount of infected cells was conducted with the help of a blue-white screening. In this assay the cells that carry a phage are blue on X-Gal plates due to the complementation of the <i>lacZ</i> gene by the phages.</p>
 +
 
 +
 
 +
  <h3 id="bacth">Conversion of BACTH into an iGEM standard and analysis of function</h3>
 +
  <a href="https://2015.igem.org/Team:TU_Dresden/Project/Description#bacth"></a>
 +
  <p style="line-height:1.8">With the combination of PACE and BACTH for our project, we are able to investigate the affinity of any two proteins of interest. Since this assay was lacking from the registry, it became evident that we could create it, built up from biobricks. So we went to work ordering T25 and T18 as biobricks as well as leucine zippers as our “proteins of interest”, positive controls and proof of principle that this assay is biobrick compatible. With a fusion ligation of the leucine zippers to their respective T25 or T18, the build up began. This was followed by a non-fusion ligation in order to piece the entire construct together. Lastly the construct was inserted downstream of a <i>lacZ</i> promoter (pLac), expressed in a cya- strain in order to obtain a read out on X-gal plates. In this assay the cells carrying the positive control and successful protein protein interaction will appear blue due to the activation of <i>lacZ</i> from newly synthesized cAMP. </p>
  
<body>
 
  
<div id="TueContent">
+
  <h3 id="setup">Set up of flow system</h3>
 +
  <a href="https://2015.igem.org/Team:TU_Dresden/Project/Description#setup"></a>
 +
  <p style="line-height:1.8">During the initial conception of the project different parameters of the cultivation system were described. All of them showed different media compositions were described as well as different volumes of the bioreactor and lagoons. This led us to the idea of optimizing and adapting the whole system to our requirements. Our main focus was on making the system more efficient by using less recourses and producing less waste. </p>
 +
<p style="line-height:1.8">The paper by Esvelt <i>et al.</i> (2011) describes a variety of PACE systems, which follow the setup in figure 1. For continuous cultivation the stirred-tank reactor was diluted with fresh medium. The same amount of medium containing <i>E. coli</i> was pumped out of the reactor. The growth of the bacteria was controlled by the dilution rates (1 – 2.5 h<sup>-1</sup>). However the smaller reactor (lagoon, 4) had a dilution of 1 h<sup>-1</sup>. Therefore the redundant liquid from the continuous stirred-tank reactor (CSR) was separated into a waste container (3). The lagoon was infected with phages which aimed to reproduce inside the <i>E. coli</i>. The final goal of the experiment was to induce an evolutionary process of the phages inside the lagoon.</p>
 +
<p style="line-height:1.8">After accomplishing a more efficient system the next step in our work was to find out how our organism grows within the bioreactor and if the plasmid is stable within the organism as well as inducible.
 +
</p>
  
<h1>Meetings</h1>
+
<figure align="center">
 +
<a href="https://static.igem.org/mediawiki/2015/b/b2/TU_Dresden_PACE_setup.jpg" title="View">
 +
  <IMG SRC="https://static.igem.org/mediawiki/2015/b/b2/TU_Dresden_PACE_setup.jpg" style="width: 80%;"/></a>
 +
<div style="font-size: 13px">
 +
  <caption>Figure 1 - Setup of the PACE systems.</caption>
 +
</div>
 +
</figure>
  
<h2>Weekly meetings</h2>
+
  <h3 id="biobrick">Biobrick assembly</h3>
<p style="line-height:1.8">Since the 20<sup>th</sup> of February we had weekly meetings on Monday with everybody from the team including the supervisors. In these meetings we discussed the progress of each person's work, the tasks for the upcoming week and also the results. Since not everyone was following what everyone was doing, the meetings were a good opportunity to catch up and discuss all together. </p>
+
  <a href="https://2015.igem.org/Team:TU_Dresden/Project/Description#biobrick"></a>
 +
  <p style="line-height:1.8">In this subproject we aimed to assemble the different elements used in our project into the iGEM Biobricks (<a style="text-decoration:none;" href="https://2015.igem.org/Team:TU_Dresden/Project/Parts"><font color="#045FB4">Parts</font></a>). These different elements are the following:.</p>
  
 +
  <ul>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">M13 gene 3 coding for infection protein P3</li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">HER2 (Human Epidermal Growth Factor 2) cytoplasmic domain</li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">ZHER2 - affibody with affinity to HER2</li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">T25 - subunit of BACTH system</li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">T18 - subunit of BACTH system</li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">Leucine zipper able to bind to T25 BACTH subunit</li>
 +
    <li style="margin-bottom: 10px;line-height:1.8;">Leucine zipper able to bind to T18 BACTH subunit</li>
 +
  </ul>
  
<h2>Group leader meetings</h2>
 
<p style="line-height:1.8">During the development of our project we had four meetings with the group leaders of the Biotechnology Center of the TU Dresden (BIOTEC). These meetings take place the first Monday of every month. The first one we attended focused on the idea we wanted to realize. The leaders helped us to think about difficulties we could face and gave valuable impulses. In the second one we presented our finance plan and they confirmed their support for an iGEM team. The third and fourth meeting were used to present the progress of our project as well as to check the finances. To sum up, we got input from diverse groups in the BIOTEC concerning both technical issues and ways to fund our group. This helped us to illuminate the project idea from numerous points of view.</p>
 
  
<h2>Meetings with iGEM veterans</h2>
+
<h3 style="text-align:center;"><a style="text-decoration:none;" href="#top"><font color="#045FB4">To the top!</font></a></h3>
<p style="line-height:1.8"> A very special opportunity for us was to meet Robert Braun, Prof. Thomas Mascher and his PhD student Julia Bartels: three iGEM veterans from the TU Bielefeld and the LMU Munic, respectively. As soon as they heard that there was an iGEM team in Dresden for the first time since many years, they contacted us and we met with them. They did not only inform us about their experiences, their work and the competition, but they gave us valuable information to fit the iGEM requirements and standards. The meetings led us to reorganize the project and make it more realistic for the competition. After these discussions we could renew our courage and we could contact them any time we needed help and advice. </p>
+
  
<h2>Meetings with companies</h2>
+
  </div>
<p style="line-height:1.8"> In order to sponsors and economical support from the scientific community in Dresden, we had to send several (hundreds) of  e-mails and meet representatives of companies. One of the companies we met twice was Biosaxoy, located in the same building as the BIOTEC. In these meetings we explained our project and goals to the representatives and we got valuable feedback from them on how to improve our project and make it more attractive to other companies. Since it was not possible for them to directly support us, they gave us several contacts from other companies and sectors.</p>
+
  
<h2>Bonding Firmenkontaktmesse</h2>
 
<p style="line-height:1.8"> On the 28<sup>th</sup> and 29<sup>th</sup> the <a href="http://dresden.firmenkontaktmesse.de/">bonding Firmenkontaktmesse</a> took place in Dresden. In this fair several companies from different fields present career opportunities and information about themselves. Two different members of the group attended the fair on both days: Bo and Bastian were there during the first day, and Marvin and Ashwin on the second. Our team members tried to approach the representatives of the companies and ask for their advice and support, but the success was quite limited.</p>
 
  
 +
</body>
 
</html>
 
</html>

Latest revision as of 11:05, 18 September 2015


Description

Introduction

Our project is called SPACE-P (Structural Phage Assisted Continuous Evolution of Proteins) and is part of the Synthetic Biology field. It focuses on accelerating the process of developing protein binding partners, which is required in pharmaceutical research as well as biotechnology and many other fields of science. Thus far phage display is the most commonly used method for the discovery of protein binding partners. In this method a large library of potential binding partners is created where the strongest candidates are selected for further affinity testing. This process is very time consuming, cost intensive, requires human intervention steps, and is limited to the size of the given library. Our platform will make it possible to start with a single molecule, transform it by mutation and selection pressure to improve the binding affinity towards a target protein. This method is not only easy to implement, utilizing simple organisms and devices, but also significantly faster and cheaper than currently used tools.

Subprojects

To establish our idea we divided the whole work into subprojects which were realized simultaniously. These subprojects should be combined later. The error finding and erasing is much easier with this approach and it is faster compared to a step by step approach where you try to start with the next step only when you succeeded the previous ones. The subprojects we worked on are the following:

Folding study of target protein

As a proof of principle we wanted to fit an affibody to the epitope of a target protein. The target we chose for our studies is a human membrane protein called human epidermal growth factor receptor 2 (HER2). To use a human protein and membrane protein is challenging since the codon usage, post-translational modifications, disulfide bridges and membrane parts have to be taken into account. To deal with this challenges we decided for a small extracellular domain that carries no post-translational modifications and disulfide bridges. This part of HER2 is involved in ligand binding and therefore is an interesting drug target. Afterwards we harmonized the codon usage to E. coli. Finally we compared the protein structure expressed from E. coli to the expected one from literature. To do so we cloned the fragment into an expression vector with a tag, purified it with a column and analyse it with circular dichroism spectroscopy.

Structure analysis of our targets and their interactions

Having the crystallized structure of the extracellular part of HER2 and the affibody ZHER2 binding to it (PDB-ID: 3MZW), we are able to perform further investigations on our targets and their interactions. Those analysis should give us a presentiment of possibilities for the directed evolution and therefore provide a benchmark for the choice of further possible targets. The following analysis are performed:

  • Structure check of HER2
  • Calculation of interfacial residues of HER2 and its bound affibody
  • Calculation of electrostatic interactions in the interface
  • Conservation study of HER2
  • Visualization of the B-factor for the affibody ZHER2

Investigation of P3 threshold for E. coli resistance

The protein III (P3) from M13 plays a key role in our concept. The deficiency of it in the M13 phage we used can be compensated by the modified E. coli. However it is known that the expression of P3 in E. coli before the infection with M13 leads to the resistance of the bacterium to the phage. This was our motivation to find the threshold of resistance. To find it we measured the amount of infected bacteria cells in the lagoon depending on the expression rate of P3. The P3 expression rate should be detected by the co-expression of a fluorescent protein while the amount of infected cells was conducted with the help of a blue-white screening. In this assay the cells that carry a phage are blue on X-Gal plates due to the complementation of the lacZ gene by the phages.

Conversion of BACTH into an iGEM standard and analysis of function

With the combination of PACE and BACTH for our project, we are able to investigate the affinity of any two proteins of interest. Since this assay was lacking from the registry, it became evident that we could create it, built up from biobricks. So we went to work ordering T25 and T18 as biobricks as well as leucine zippers as our “proteins of interest”, positive controls and proof of principle that this assay is biobrick compatible. With a fusion ligation of the leucine zippers to their respective T25 or T18, the build up began. This was followed by a non-fusion ligation in order to piece the entire construct together. Lastly the construct was inserted downstream of a lacZ promoter (pLac), expressed in a cya- strain in order to obtain a read out on X-gal plates. In this assay the cells carrying the positive control and successful protein protein interaction will appear blue due to the activation of lacZ from newly synthesized cAMP.

Set up of flow system

During the initial conception of the project different parameters of the cultivation system were described. All of them showed different media compositions were described as well as different volumes of the bioreactor and lagoons. This led us to the idea of optimizing and adapting the whole system to our requirements. Our main focus was on making the system more efficient by using less recourses and producing less waste.

The paper by Esvelt et al. (2011) describes a variety of PACE systems, which follow the setup in figure 1. For continuous cultivation the stirred-tank reactor was diluted with fresh medium. The same amount of medium containing E. coli was pumped out of the reactor. The growth of the bacteria was controlled by the dilution rates (1 – 2.5 h-1). However the smaller reactor (lagoon, 4) had a dilution of 1 h-1. Therefore the redundant liquid from the continuous stirred-tank reactor (CSR) was separated into a waste container (3). The lagoon was infected with phages which aimed to reproduce inside the E. coli. The final goal of the experiment was to induce an evolutionary process of the phages inside the lagoon.

After accomplishing a more efficient system the next step in our work was to find out how our organism grows within the bioreactor and if the plasmid is stable within the organism as well as inducible.

Figure 1 - Setup of the PACE systems.

Biobrick assembly

In this subproject we aimed to assemble the different elements used in our project into the iGEM Biobricks (Parts). These different elements are the following:.

  • M13 gene 3 coding for infection protein P3
  • HER2 (Human Epidermal Growth Factor 2) cytoplasmic domain
  • ZHER2 - affibody with affinity to HER2
  • T25 - subunit of BACTH system
  • T18 - subunit of BACTH system
  • Leucine zipper able to bind to T25 BACTH subunit
  • Leucine zipper able to bind to T18 BACTH subunit

To the top!